Travere Therapeutics Stock Buy Hold or Sell Recommendation
| TVTX Stock | USD 19.73 0.60 3.14% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Travere Therapeutics is 'Buy'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Travere Therapeutics given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Travere Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Travere Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide. In addition, we conduct extensive research on individual companies such as Travere and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Travere Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Travere |
Execute Travere Therapeutics Buy or Sell Advice
The Travere recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Travere Therapeutics. Macroaxis does not own or have any residual interests in Travere Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Travere Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Buy
Market Performance | Modest | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Travere Therapeutics Trading Alerts and Improvement Suggestions
| Travere Therapeutics had very high historical volatility over the last 90 days | |
| Travere Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 233.18 M. Net Loss for the year was (320.63 M) with profit before overhead, payroll, taxes, and interest of 7.93 M. | |
| Travere Therapeutics currently holds about 553.17 M in cash with (237.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.65. | |
| Travere Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 |
Travere Therapeutics current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Travere analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Travere analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Travere Therapeutics Returns Distribution Density
The distribution of Travere Therapeutics' historical returns is an attempt to chart the uncertainty of Travere Therapeutics' future price movements. The chart of the probability distribution of Travere Therapeutics daily returns describes the distribution of returns around its average expected value. We use Travere Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Travere Therapeutics returns is essential to provide solid investment advice for Travere Therapeutics.
| Mean Return | 0.11 | Value At Risk | -4.79 | Potential Upside | 6.29 | Standard Deviation | 3.70 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Travere Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Travere Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Travere Therapeutics, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Travere Therapeutics back and forth among themselves.
| Shares | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 2.2 M | Emerald Advisers, Llc | 2024-12-31 | 2.1 M | Woodline Partners Lp | 2024-12-31 | 2.1 M | Geode Capital Management, Llc | 2024-12-31 | 1.8 M | Kynam Capital Management, Lp | 2024-12-31 | 1.8 M | Nuveen Asset Management, Llc | 2024-12-31 | 1.7 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.7 M | Bank Of America Corp | 2024-12-31 | 1.3 M | Bnp Paribas Arbitrage, Sa | 2024-12-31 | 1.2 M | Blackrock Inc | 2024-12-31 | 8 M | Armistice Capital, Llc | 2024-12-31 | 7.4 M |
Travere Therapeutics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 22.3M | 81.0M | (104.1M) | (3.5M) | 359K | 341.1K | |
| Free Cash Flow | (162.6M) | (38.9M) | (214.8M) | (322.3M) | (338.7M) | (321.8M) | |
| Depreciation | 24.6M | 26.6M | 33.1M | 38.5M | 43.6M | 45.7M | |
| Other Non Cash Items | 102.5M | 23.8M | 19.0M | 39.0M | 2.7M | 2.6M | |
| Capital Expenditures | 119.8M | 24.2M | 28.6M | 668K | 101.2M | 106.3M | |
| Net Income | (169.4M) | (180.1M) | (278.5M) | (376.3M) | (320.6M) | (304.6M) | |
| End Period Cash Flow | 84.8M | 165.8M | 61.7M | 58.2M | 58.5M | 58.4M | |
| Change To Inventory | (5.1M) | (1.8M) | (2.1M) | (39.4M) | 2.8M | 3.0M | |
| Investments | 58.5M | (113.5M) | (3.4M) | 36.0M | 99.3M | 104.3M | |
| Change To Netincome | 55.3M | 117.7M | 23.2M | 41.6M | 37.4M | 43.7M |
Travere Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Travere Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Travere Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Travere stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.28 | |
β | Beta against Dow Jones | 1.67 | |
σ | Overall volatility | 3.77 | |
Ir | Information ratio | 0.06 |
Travere Therapeutics Volatility Alert
Travere Therapeutics shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Travere Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Travere Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Travere Therapeutics Fundamentals Vs Peers
Comparing Travere Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Travere Therapeutics' direct or indirect competition across all of the common fundamentals between Travere Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Travere Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Travere Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Travere Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Travere Therapeutics to competition |
| Fundamentals | Travere Therapeutics | Peer Average |
| Return On Equity | -2.47 | -0.31 |
| Return On Asset | -0.23 | -0.14 |
| Profit Margin | (1.38) % | (1.27) % |
| Operating Margin | (0.79) % | (5.51) % |
| Current Valuation | 1.78 B | 16.62 B |
| Shares Outstanding | 88.74 M | 571.82 M |
| Shares Owned By Insiders | 0.62 % | 10.09 % |
| Shares Owned By Institutions | 99.38 % | 39.21 % |
| Number Of Shares Shorted | 11.3 M | 4.71 M |
| Price To Book | 29.64 X | 9.51 X |
| Price To Sales | 7.51 X | 11.42 X |
| Revenue | 233.18 M | 9.43 B |
| Gross Profit | 7.93 M | 27.38 B |
| EBITDA | (265.77 M) | 3.9 B |
| Net Income | (320.63 M) | 570.98 M |
| Cash And Equivalents | 553.17 M | 2.7 B |
| Cash Per Share | 8.65 X | 5.01 X |
| Total Debt | 401.58 M | 5.32 B |
| Debt To Equity | 2.60 % | 48.70 % |
| Current Ratio | 4.71 X | 2.16 X |
| Book Value Per Share | 0.68 X | 1.93 K |
| Cash Flow From Operations | (237.47 M) | 971.22 M |
| Short Ratio | 5.73 X | 4.00 X |
| Earnings Per Share | (4.07) X | 3.12 X |
| Price To Earnings To Growth | (0.02) X | 4.89 X |
| Target Price | 33.8 | |
| Number Of Employees | 385 | 18.84 K |
| Beta | 0.75 | -0.15 |
| Market Capitalization | 1.75 B | 19.03 B |
| Total Asset | 594.12 M | 29.47 B |
| Retained Earnings | (1.45 B) | 9.33 B |
| Working Capital | 215.95 M | 1.48 B |
| Net Asset | 594.12 M |
Note: Acquisition by Poole Sandra of 6500 shares of Travere Therapeutics subject to Rule 16b-3 [view details]
Travere Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Travere . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Travere Therapeutics Buy or Sell Advice
When is the right time to buy or sell Travere Therapeutics? Buying financial instruments such as Travere Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Travere Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cannabis Thematic Idea Now
Cannabis
Equities that are involved in production and delivery of legal cannabis. This theme is designed for investors that are willing to accept higher levels of market risk inherited by cannabis production and distribution globally. The Cannabis theme has 27 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cannabis Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Travere Stock Analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.